Affimed N.V. (AFMD)

Market Cap	19.51M
Revenue (ttm)	6.29M
Net Income (ttm)	-78.04M
Shares Out	16.39M
EPS (ttm)	-5.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	417,938
Open	1.180
Previous Close	1.180
Day's Range	1.144 - 1.250
52-Week Range	1.144 - 8.950
Beta	2.06
Analysts	Strong Buy
Price Target	13.50 (+1,034.45%)
Earnings Date	Nov 14, 2024

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 12, 2014
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: AFMD
• Website: https://www.affimed.com

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 5 analysts, the average rating for AFMD stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,034.45% from the latest price.

Price Target

$13.5

(1,034.45% upside)

Analyst Consensus: Strong Buy